吉非替尼,临床注释-2,变异和临床注释数据

吉非替尼

临床注释ID

981420042

药物名称(英)

gefitinib

变异单倍型

rs121434568

基因

EGFR

证据级别

水平覆盖

水平修饰符

Rare Variant

表现型类别(英)

Efficacy

表现型类别

功效

分数

190.5

PMID计数

计数的证据

表现型

癌，非小细胞肺

表现型(英)

Carcinoma, Non-Small-Cell Lung

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981420042

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1018	TT	Patients with advanced non-small-cell lung cancer and who do not carry an activating somatic EGFR mutation, for example the TT genotype at rs121434568 (also known as L858R), may have a decreased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who have an activating EGFR mutation, for example the GG or GT genotypes at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.
1017	GT	Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GT genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.
1016	GG	Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GG genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.

临床证据

id	证据的ID	总结
1926	827926134	Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.
1925	981477381	Allele G is not associated with overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1924	981477373	Allele G is not associated with progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1923	981477365	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1922	981477357	Allele G is not associated with Overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1921	981477349	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1920	981477340	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.
1919	981475368	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1918	981475201	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.
1917	981475192	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.
1916	981419813	Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.
1915	981419803	Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.
1914	981419755	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1913	981419746	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1912	981419736	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1911	981419727	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1910	981419719	Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.
1909	981419710	Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.
1908	981419668	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1907	981419653	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1906	981419643	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.
1905	981419634	Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.
1904	981419624	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1903	981419616	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1902	981419607	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1901	981419598	Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1900	981419589	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1899	981419477	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.
1898	981419469	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1897	981419460	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1896	981419441	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1895	981419331	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.
1894	981419322	Allele G is associated with increased response rates when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1893	981419236	Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.
1892	981419226	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.
1891	981417305	Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.
1890	981417296	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1889	981417279	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1888	981417256	Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1887	981417247	Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1886	981417228	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1885	981417211	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.
1884	1446908159	Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.
1883	1446908230	Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.
1882	PA166104789	Annotation of FDA Label for gefitinib and EGFR

临床病史

id	类型	评论
773	Update	CA score added as part of scoring system release. LOE assigned following curator review.
772	Update	Attached FDA label and removed override.
771	Update	Added additional VAs from PMIDs 22760226 and 22370314, rewrote phenotype descriptions, changed LOE to 1A as there is a supporting FDA label
770	Update	corrected a small typo (added the word "to" to all sentences).

最新招商产品更多>>